Therapy Interrupted
46 drugs15,370 FAERS reportsMedDRA PT
GET
/api/v1/reaction/therapy-interruptedReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
Drugs reporting Therapy Interrupted (46)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Relacorilant133%
- 2Relugolix3,76716%
- 3Brensocatib9612%
- 4Voclosporin95811%
- 5Amikacin1,3787.6%
- 6Givosiran936.8%
- 7Brodalumab1286.6%
- 8Sotagliflozin336.4%
- 9Lotilaner1445.8%
- 10Garadacimab175.5%
- 11Metreleptin665.4%
- 12Rifaximin1,0575.2%
- 13Tenapanor625.0%
- 14Cipaglucosidase Alfa34.8%
- 15Lonapegsomatropin264.7%
- 16Bimekizumab7354.6%
- 17Rozanolixizumab404.5%
- 18Zilucoplan304.4%
- 19Quinidine1614.2%
- 20Resmetirom624.1%
- 21Cenegermin4874.1%
- 22Voxelotor9004.0%
- 23Trientine173.7%
- 24Vutrisiran793.7%
- 25Avacopan1993.5%
- 26Atogepant1923.1%
- 27Eslicarbazepine983.1%
- 28Norethindrone5323.0%
- 29Belzutifan372.8%
- 30Patisiran762.7%
- 31Burosumab1662.7%
- 32Pemigatinib212.7%
- 33Sonidegib372.5%
- 34Ponesimod82.5%
- 35Sebetralstat42.3%
- 36Upadacitinib1,8002.3%
- 37Mavacamten1002.3%
- 38Lumasiran82.3%
- 39Vibegron1652.3%
- 40Ixekizumab8262.3%
- 41Crizanlizumab282.0%
- 42Baricitinib1781.9%
- 43Clascoterone211.5%
- 44Deucravacitinib371.4%
- 45Tildrakizumab171.0%
- 46Brivaracetam480—
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
- Hospitalisation19 shared · 0.12
- Therapy Cessation7 shared · 0.12
- Insurance Issue5 shared · 0.10
- Intentional Dose Omission5 shared · 0.09
- Product Availability Issue5 shared · 0.09
- Product Dose Omission Issue38 shared · 0.08
- Product Use Issue14 shared · 0.08
- Inappropriate Schedule Of Product Administration12 shared · 0.08
- Illness7 shared · 0.07
- Inability To Afford Medication3 shared · 0.06
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.